Related Experiment Video
Updated: Jul 10, 2025
Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells
Published on: August 21, 2013
Strategies for the Management of Patients with Pancreatic Cancer with PARP Inhibitors
Talia Golan1, Maria Raitses-Gurevich2, Tamar Beller2
1Cancer Center, Chaim Sheba Medical Center and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. Talia.Golan@sheba.health.gov.il.
Abstract:
A subset of patients with pancreatic adenocarcinomas (PDAC) harbor mutations that are exploitable in the context of DNA-damage response and repair (DDR) inhibitory strategies. Between 8-18% of PDACs harbor specific mutations in the DDR pathway such as BRCA1/2 mutations, and a higher prevalence exists in high-risk populations (e.g., Ashkenazi Jews). Herein, we will review the current trials and data on the treatment of PDAC patients who harbor such mutations and who appear sensitive to platinum and/or poly ADP ribose polymerase inhibitor (PARPi) based therapies due to a concept known as synthetic lethality. Although this current best-in-class precision treatment shows clinical promise, the specter of resistance limits the extent of therapeutic responses. We therefore also evaluate promising pre-clinical and clinical approaches in the pipeline that may either work with existing therapies to break resistance or work separately with combination therapies against this subset of PDACs.
Insights
Certain pancreatic cancers (PDAC) with DNA repair mutations benefit from targeted therapies like PARP inhibitors. However, resistance limits effectiveness, prompting research into new combination treatments for better outcomes.
Area of Science:
- Oncology
- Genetics
- Pharmacology
Background:
- Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignancy with limited treatment options.
- A subset of PDAC patients (8-18%) harbor DNA-damage response (DDR) pathway mutations, including BRCA1/2.
- These mutations are more common in specific high-risk populations.
Purpose of the Study:
- To review current clinical trials and data on treating PDAC patients with DDR mutations.
- To explore the efficacy of platinum and poly ADP ribose polymerase inhibitor (PARPi) therapies based on synthetic lethality.
- To evaluate emerging pre-clinical and clinical strategies to overcome treatment resistance.
Main Methods:
- Literature review of clinical trials and pre-clinical studies.
- Analysis of data on PDAC patients with DDR mutations treated with platinum and PARPi therapies.
- Evaluation of novel therapeutic approaches and combination strategies.
Main Results:
- Synthetic lethality strategies, particularly PARPi and platinum agents, show clinical promise in a subset of PDAC patients with DDR mutations.
- Acquired or intrinsic resistance to these therapies is a significant limitation to durable responses.
- Several promising pre-clinical and clinical strategies are under investigation to address resistance.
Conclusions:
- Targeting DDR pathways via synthetic lethality offers a precision medicine approach for a subset of PDAC.
- Overcoming resistance mechanisms is crucial for improving therapeutic efficacy.
- Combination therapies and novel agents hold promise for enhancing treatment outcomes in resistant PDAC.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:56Treatment Resistant Cancers
01:29Chronic Pancreatitis II: Collaborative Care
Assessment:
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:26Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...